Get the Stockscreener App
34.74
2.36%
1.2578
Beam Therapeutics Inc stock is traded at $34.74, with a volume of 162.75K.
It is up +2.36% in the last 24 hours and up +18.34% over the past month.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
See More
Previous Close:
$33.48
Open:
$33.82
24h Volume:
162.75K
Relative Volume:
0.07
Market Cap:
$3.58B
Revenue:
$164.01M
Net Income/Loss:
$-65.04M
P/E Ratio:
-50.56
EPS:
-0.687
Net Cash Flow:
$-383.84M
1W Performance:
+1.00%
1M Performance:
+18.34%
6M Performance:
+26.27%
1Y Performance:
+72.38%
1-Day Range:
$33.77
$34.79
1-Week Range:
$32.84
$36.75
52-Week Range:
$15.60
$36.88
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
34.79 | 3.53B | 164.01M | -65.04M | -383.84M | -0.687 |
VRTX
Vertex Pharmaceuticals Inc
|
510.99 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
633.38 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
930.01 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
307.74 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.75 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-26 | Initiated | Canaccord Genuity | Buy |
| Oct-09-25 | Initiated | Jefferies | Buy |
| Mar-28-25 | Upgrade | BofA Securities | Neutral → Buy |
| Mar-10-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Jan-29-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Beam Therapeutics (BEAM) CEO exercises options and sells 50K shares under plan - Stock Titan
BEAMBeam Therapeutics Inc Latest SEC Filings - Finviz
Hedge Fund and Insider Trading News: Paul Singer, Warren Buffett, Ray Dalio, George Soros, Millennium Management, Point72 Asset Management, Citadel Investment Group, CG Oncology Inc (CGON), Beam Therapeutics Inc (BEAM), and More - Insider Monkey
BEAM News | BEAM THERAPEUTICS INC (NASDAQ:BEAM) - ChartMill
Beam Therapeutics(BEAM.US) 10% Shareholder Sells US$10.04 Million in Common Stock - Moomoo
Form 144 BEAM THERAPEUTICS INC. For: 29 June By Investing.com - Investing.com South Africa
FMR LLC sells $10.04 million in Beam Therapeutics shares By Investing.com - Investing.com Australia
BEAM (NASDAQ: BEAM) insider files to sell 25,000 shares via option exercise - Stock Titan
Form 4 Beam Therapeutics Inc For: 29 June By Investing.com - Investing.com Nigeria
FMR LLC sells $10.04 million in Beam Therapeutics shares - Investing.com
FMR LLC (BEAM) trims Beam Therapeutics stake with 284,860-share open-market sale - Stock Titan
Beam Therapeutics Inc.(NasdaqGS: BEAM) added to Russell 2000 Value Benchmark - marketscreener.com
Beam Therapeutics Inc.(NasdaqGS: BEAM) added to Russell 3000E Value Benchmark - marketscreener.com
BEAM Stock's Gains Fade Despite Promising Data Rare Liver Disease Treatment Data - Stocktwits
Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade) (NASDAQ:BEAM) - Seeking Alpha
Beam Therapeutics, Inc. Actuals & Estimates (NASDAQ:BEAM) - TradingView
Top Beam Therapeutics (BEAM) Competitors 2026 - MarketBeat
BEAM Forecast — Price Target — Prediction for 2027 - TradingView
Beam Therapeutics, Inc. Actuals & Estimates (BMV:BEAM) - TradingView
Price to sales forward of Beam Therapeutics Inc. – NASDAQ:BEAM - TradingView
Enterprise value to EBIT forward of Beam Therapeutics Inc. – NASDAQ:BEAM - TradingView
Enterprise value to EBITDA forward of Beam Therapeutics Inc. – NASDAQ:BEAM - TradingView
Beam Therapeutics (BEAM) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
The Technical Signals Behind (BEAM) That Institutions Follow - Stock Traders Daily
Wedbush Maintains Beam Therapeutics(BEAM.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Beam Therapeutics stock soars 21% in three months: Here's why - MSN
Beam Therapeutics president exercises 35,505 options | BEAM Insider Trading - Stock Titan
Beam Therapeutics stock hits 52-week high at 36.66 USD By Investing.com - Investing.com Australia
Beam Therapeutics stock hits 52-week high at 36.66 USD - Investing.com
Clinical: Beam Advances Base Editing For PKU - CRISPR Medicine News
Beam Therapeutics Inc (BEAM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria - The Globe and Mail
Beam Therapeutics (BEAM) Receives FDA Approval for BEAM-304 IND Application - GuruFocus
Beam gets FDA clearance for BEAM-304 PKU gene-editing trial - Stock Titan
Beam Therapeutics gets FDA clearance for BEAM-304 - grafa.com
Beam Therapeutics gets FDA clearance for PKU gene therapy trial - Investing.com
Beam Therapeutics gets FDA clearance for PKU gene therapy trial By Investing.com - Investing.com South Africa
Beam Therapeutics Inc (BEAM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Beam Therapeutics Announces Clearance of Investigational - GlobeNewswire
Beam Therapeutics Inc (BEAM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beam Therapeutics Inc (BEAM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Beam Therapeutics Inc (BEAM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Beam Therapeutics Inc (BEAM) Institutional Confidence - TradingKey
BEAM Stock Price, Quote & Chart - ChartMill
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why - The Globe and Mail
Is Beam Therapeutics Inc. (BEAM) One of the Best Genomics Stocks to Buy According to Analysts? - Insider Monkey
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):